A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

• Status: Recruiting
• Trial end date: 2026-04-15
• Target enrollment: 0
• Participant gender: All

Summary

The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis. Participants will be assigned to one of the 3 study treatments (TAK-279, apremilast (an approved treatment), or a placebo). Participants will be in the study for up to 56 weeks.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Takeda
• Treatments: Apremilast

Criteria

Inclusion Criteria:

1. Plaque psoriasis for at least 6 months.

2. Moderate to severe disease.

3. Candidate for phototherapy or systemic therapy.

Exclusion Criteria:

1. Other forms of psoriasis.

2. History of recent infection.

3. Prior exposure to TAK-279 or active comparator.

Other protocol defined inclusion/exclusion criteria apply.